BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy” ). Another pharma developing a similar combination is Amgen Inc. (NASDAQ:AMGN). Its Imlygic talimogene laherparepvec (T-Vec...
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...
BioCentury | Dec 19, 2019

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BioCentury | Oct 4, 2019

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

The heyday of digital health may not yet even be on the horizon, but investments in the field are certainly starting to hit the radar in the areas most likely to impact patients first --...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the company said that based on the results of dialogue with FDA, it will submit an NDA next quarter...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...are on Amgen Inc.’s Phase III melanoma trial which couples its oncolytic virus Imlygic talimogene laherparepvec (T-Vec... hinging on whether viruses improve checkpoint responses,” said Kuan. A Phase II trial tested Imlygic...
...could change Imlygic’s trajectory. Øystein Soug, CEO of Targovax A/S, said that if successful, the Imlygic-Keytruda...
BioCentury | Aug 2, 2019
Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

...the field. Like Pexa-Vec, T-Vec delivers GM-CSF, but the vaccine is a herpes simplex virus. T-Vec...
Items per page:
1 - 10 of 511